Tikcro Technologies Ltd. operates as a biopharmaceutical company. It pursues an early stage biotechnology project generating new antibodies for cancer treatment addressing immune modulation. This project is based on technology from the Weizmann Institute of Science in Israel. It promotes a new approach for the generation of antibodies which are expected to have selectivity and blocking capabilities and, as a result, are expected to effectively modulate the immune system. Tikcro Technologies was founded on December 14, 1999 and is headquartered in Ness Ziona, Israel.